
Claudio Jommi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9770172/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	New funding arrangements in the Italian National Health Service. International Journal of Health Planning and Management, 2001, 16, 347-368.	1.7	66
2	Pharmaceutical regulation in 15 European countries review. Health Systems in Transition, 2016, 18, 1-122.	5.2	45
3	Implementation of Value-based Pricing for Medicines. Clinical Therapeutics, 2020, 42, 15-24.	2.5	43
4	The new pharmaceutical policy in Italy. Health Policy, 1998, 46, 21-41.	3.0	39
5	The role of health technology assessment bodies in shaping drug development. Drug Design, Development and Therapy, 2014, 8, 2273.	4.3	39
6	De innovatione: The concept of innovation for medical technologies and its implications for healthcare policy-making. Health Policy and Technology, 2016, 5, 47-64.	2.5	38
7	The impact of HTA and procurement practices on the selection and prices of medical devices. Social Science and Medicine, 2017, 174, 89-95.	3.8	32
8	Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?. PharmacoEconomics - Open, 2021, 5, 285-298.	1.8	31
9	Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency. Health Policy, 2019, 123, 595-600.	3.0	30
10	The Last Decade of Italian Pharmaceutical Policy. Pharmacoeconomics, 2008, 26, 5-15.	3.3	26
11	Public administration and R&D localisation by pharmaceutical and biotech companies: A theoretical framework and the Italian case-study. Health Policy, 2007, 81, 117-130.	3.0	17
12	The impact of generic reference pricing in Italy, a decade on. European Journal of Health Economics, 2013, 14, 959-969.	2.8	16
13	Multi-tier drugs assessment in a decentralised health care system. The Italian case-study. Health Policy, 2013, 112, 241-247.	3.0	16
14	Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system. BMJ Open, 2021, 11, e041259.	1.9	12
15	Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. BMJ Open, 2021, 11, e049128.	1.9	12
16	Market access management by pharmaceutical companies in a complex environment: The Italian case study. Journal of Medical Marketing, 2012, 12, 93-103.	0.2	7
17	Variables affecting pricing of orphan drugs: the Italian case. Orphanet Journal of Rare Diseases, 2021, 16, 439.	2.7	6
18	Innovation and Drugs Price and Reimbursement: A Comparison between Italy and the other Major EU Countries. Global & Regional Health Technology Assessment, 2015, 2, GRHTA.5000206.	0.1	5

CLAUDIO JOMMI

#	Article	IF	CITATIONS
19	The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study. European Journal of Health Economics, 2016, 17, 963-977.	2.8	5
20	Accesso precoce al mercato: dalle approvazioni condizionate di EMA agli accordi negoziali particolari di AIFA. Global & Regional Health Technology Assessment, 2018, 2018, 228424031879244.	0.1	5
21	Clinical Management of Chronic Kidney Disease Patients in Italy: Results from the IRIDE Study. Nephron, 2018, 140, 39-47.	1.8	5
22	The economic impact of compassionate use of medicines. BMC Health Services Research, 2021, 21, 1303.	2.2	5
23	Current Pipelines for Neglected Diseases. PLoS Neglected Tropical Diseases, 2014, 8, e3092.	3.0	3
24	Patient access to oral nutritional supplements: Which policies count?. Nutrition, 2020, 69, 110560.	2.4	3
25	The assessment of new drugs for asthma and COPD: a Delphi study examining the perspectives of Italian payers and clinicians. Multidisciplinary Respiratory Medicine, 2015, 11, 4.	1.5	2
26	La politica farmaceutica in Italia nell'ultimo decennio: instabilità o consolidamento?. Pharmacoeconomics Italian Research Articles, 2008, 10, 1-12.	0.2	1